Trial Profile
A Phase II Study of Gemcitabine and TS-1 in Patients With Previously Untreated Metastatic or Recurrent Biliary Tract Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2015
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- Acronyms GetBil
- 01 Feb 2012 Actual patients number is 19 as reported by ClinicalTrials.gov.
- 05 Aug 2010 New trial record